depcomswinnerscircle@gmail.com
Followers | 118 |
Posts | 10,219 |
Boards Moderated | 2 |
Alias Born | 06/08/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$APTO - .86 bottom bounce play.
52 week low was .78 with a high of $4.29 there could be a substantial move
Market Cap is 16.52 Million
Recently reported they will announce higher cash flow from 4th quarter 2016 to first quarter 2017. Conference call scheduled for May 11, 2017.
https://finance.yahoo.com/news/aptose-release-first-quarter-ended-123000384.html
$APTO big buys starting to hit.
$APTO a nice bottom play at .86
$APTO starter position at .89 pps
$PLUG trending upward after hours.
$PLUG on a slight pullback but only a nudge under 50 day moving average and only a few cents below 200 day moving average. If we can break the 200 day we could see a sustained move from here.
$ZPAS took a 35-40% profit the other day but still moving up steadily.
FRZT with a target of .0008 as initial target.
$PLUG up another .09 cents. No major resistance. I would place my target at $4
Current starter positions in $GLUU, $ZPAS & $RJDG
$EAPH going to have upside in the coming month. Expecting more updates this month as per PR.
Easton Pharmaceuticals and BMV Medica Announces First Shipment of “Gynofit” To Multi-National Pharmaceutical Company
Source: InvestorsHub NewsWire
Easton Pharmaceuticals and BMV Medica Announces First Shipment of “Gynofit” To Multi-National Pharmaceutical Company, Gedeon Richter, Towards Its Purchase Order, Has Been Received For February 16th Product Launch in Puerto Vallarta, Mexico
TORONTO, ON -- February 3, 2017 -- InvestorsHub NewsWire -- Easton Pharmaceuticals, Inc. (OTC:EAPH) announces after having received initial payment towards product purchase from pharmaceutical multi-national Gedeon Richter’s Plc subsidiary - Gedeon Richter Mexico S.A.P.I. de C.V., the first shipment of “Gynofit” bacterial vaginosis treatment has been shipped and received in Mexico in preparation of its product launch in Puerto Vallarta, Mexico for February 16th.
Gedeon Richter will be showcasing the products as it launches its marketing and sales program with a steadily increasing marketing budget over the next 3 years. Easton / BMV will provide sales figures and projections sometime in the next quarter.
"Gynofit" is a natural product treatment for women diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. As previously announced, the agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing plan for Gynofit and its success, which Easton / BMV and Gedeon Richter believe will steadily drive sales in Mexico over the next three years and beyond.
Other News
Easton Pharmaceuticals continues to move forward with its due diligence for the acquisition of revenue generating iBliss Inc., as previously announced and expects to have the transaction completed sometime this month once all terms of the agreement have been agreed to and finalized.
Easton is also confirming that it has entered into negotiations towards acquiring a second revenue generating company possessing strong international sales which could coincide with the closing of iBliss and BMV Medica S.A.
Easton is also in late stage negotiations towards 2 (two) agreements with two 2 (two) medical marijuana companies, one in Jamaica and the other in the US, both expecting to potentially add significant and near term sales to Easton. Updates are expected this month or as they materialize.
Easton also confirms that late stage negotiations are continuing towards Eastons / BMV Medica’s other licensed products (VS-Sense, AL-Sense). Detailed updates expected very shortly
For More Detailed Information On iBliss Visit:
https://iblissvapor.com
For More Detailed Information on Gedeon Richter Plc Visit:
http://www.richter.hu/en-US/Pages/default.aspx
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products from CommonSense of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine's Ontario, Canada.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.bmvmedica.net
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact Information
Evan Karras
CEO
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
$NGD, $PPCH, $EFFI, $SFOR, $PTX
$SFOR up 44%
$PPCH IN AT .0159
PTX should start moving.
$PTX at .58 took a position here
$FREEF - volume is still good, trying to break through .02.
.02 break would be a very positive sign.
$EFFI TRYING TO BREAK .0010 wall here as well. This could be a good run if we break the wall. Company updates have been positive.
$EFFI UP 50% been waiting on this one to bounce back for me.
$FREEF 944,500 share buy at .0128
$FREEF Closed up 14% - initial position opened today at .0135 - 36,000 shares. Target .03-.04. Looking forward to Monday ????
$FREEF UP 10%
$FREEF support building at .0013/.0014 level
Added $FREEF at .0135. Volume has been picking up and we could see a spike. My target is .03 - .04
Nice move, glad I held.
Fidelity still doesn't have me set up to transact orders on FREE
Was able to grab some 4's. Looks like this could finally pay off.
Added $SDOC at .093
$BAA News Out ------ News out: Banro Reports Further High Grade Drill Results and New Mineralized Zone at Namoya
- Drilling at Namoya intersects significant mineralization, including 10.00 metres grading 18.48 g/t Au, 29.00 metres grading 3.84 g/t Au, 16.00 metres grading 4.16 g/t Au, 6.00 metres grading 17.65 g/t Au and 42.00 metres grading 2.29 g/t Au.
- New mineralised zone; Namoya Summit Hanging Wall, discovered at Namoya.
http://www.banro.com/assets/docs/RC-intercections-Feb-2016.pdf
Still holding and added into the close . Looks like volume is coming back.
Timing is everything here. I agree on your statement.
See but your here because there will be an opportunity.
We know one thing it's volatile. When it runs it runs hard. Timing is everything.
one day at a time.
Be nice to see this move back over .07 and move up steadily to the teens.
Could dip quick here, needs bid support.
10Q was released
Agree, looking forward to making some profit. I believe we are looking at .25-.30 reasonably just need to build a bit more on the bid.
PVHO still looks thin, entered this morning just under .13
EFFI shares being held tight, no shaking free shares.
Nice update by the EFFI!